Hims is one of the many platforms that offer telehealth online from licensed providers, with services spanning from skincare and hair loss to anxiety and erectile dysfunction. In this review ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

There is also a chance that a weaker macroeconomy and slowing consumer spending may encourage more consumers to review their ...

Hims & Hers Health Inc ... Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at ...

Leerink Partners analyst Michael Cherny has maintained their neutral stance on HIMS stock, giving a Hold rating yesterday. Michael ...

While Hims, Inc. has an A+ rating with the Better Business Bureau, some customer reviews are less than stellar. As of August 2024, the company’s overall 3.86 average rating out of 5 stars has to ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.